PMC:7029759 / 9688-11523
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
236 | 41-50 | Species | denotes | 2019-nCoV | Tax:2697049 |
237 | 141-150 | Species | denotes | 2019-nCoV | Tax:2697049 |
238 | 470-478 | Species | denotes | CoV-2019 | Tax:2697049 |
239 | 669-678 | Species | denotes | 2019-nCoV | Tax:2697049 |
240 | 686-696 | Species | denotes | SARS virus | Tax:694009 |
241 | 1425-1430 | Species | denotes | Ebola | Tax:1570291 |
242 | 302-318 | Chemical | denotes | oligonucleotides | MESH:D009841 |
243 | 606-621 | Chemical | denotes | oligonucleotide | MESH:D009841 |
244 | 801-817 | Chemical | denotes | oligonucleotides | MESH:D009841 |
245 | 908-913 | Chemical | denotes | lipid | MESH:D008055 |
246 | 1089-1098 | Disease | denotes | infection | MESH:D007239 |
247 | 1344-1359 | Disease | denotes | viral infection | MESH:D001102 |
248 | 1661-1669 | Disease | denotes | infected | MESH:D007239 |
249 | 184-194 | CellLine | denotes | MN908947.3 | CVCL:U508 |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T182 | 21-28 | GO:0009986 | denotes | surface |
T181 | 41-50 | SP_7 | denotes | 2019-nCoV |
T180 | 82-88 | SO:0001026 | denotes | genome |
T179 | 122-128 | SO:0001026 | denotes | genome |
T178 | 141-150 | SP_7 | denotes | 2019-nCoV |
T177 | 259-280 | SO:0000646 | denotes | small interfering RNA |
T176 | 282-287 | SO:0000646 | denotes | siRNA |
T175 | 292-301 | SO:0000077 | denotes | antisense |
T174 | 339-344 | NCBITaxon:10239 | denotes | virus |
T173 | 366-372 | SO:0001026 | denotes | genome |
T172 | 459-466 | SO:0000417 | denotes | domains |
T171 | 560-565 | SO:0000646 | denotes | siRNA |
T170 | 586-591 | NCBITaxon:10239 | denotes | viral |
T169 | 650-656 | SO:0001026 | denotes | genome |
T168 | 657-665 | SO:0000853 | denotes | homology |
T167 | 669-678 | SP_7 | denotes | 2019-nCoV |
T166 | 686-696 | NCBITaxon:10633 | denotes | SARS virus |
T165 | 846-851 | UBERON:0000170 | denotes | lungs |
T164 | 908-913 | CHEBI:18059;CHEBI:18059 | denotes | lipid |
T163 | 968-973 | UBERON:0000170 | denotes | lungs |
T162 | 1012-1017 | SO:0000646 | denotes | siRNA |
T161 | 1071-1076 | UBERON:0000170 | denotes | lungs |
T160 | 1167-1175 | UBERON:0004821;CL:0000322 | denotes | alveolar |
T159 | 1176-1186 | CL:0000322;UBERON:0004821 | denotes | epithelial |
T158 | 1187-1192 | CL:0000322 | denotes | cells |
T157 | 1200-1204 | UBERON:0002048 | denotes | lung |
T156 | 1209-1214 | SO:0000646 | denotes | siRNA |
T155 | 1288-1292 | SO:0000704 | denotes | gene |
T154 | 1344-1349 | NCBITaxon:10239 | denotes | viral |
T153 | 1400-1405 | SO:0000646 | denotes | siRNA |
T152 | 1495-1501 | NCBITaxon:33208 | denotes | animal |
T151 | 1550-1555 | SO:0000646 | denotes | siRNA |
T150 | 1638-1643 | SO:0000646 | denotes | siRNA |
T149 | 1644-1649 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
T148 | 1690-1695 | SO:0000646 | denotes | siRNA |
T147 | 1815-1826 | CHEBI:23888;CHEBI:23888 | denotes | medications |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T41 | 29-37 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
T42 | 78-81 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T43 | 82-88 | Body_part | denotes | genome | http://purl.org/sig/ont/fma/fma84116 |
T44 | 118-121 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T45 | 122-128 | Body_part | denotes | genome | http://purl.org/sig/ont/fma/fma84116 |
T46 | 277-280 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T47 | 362-365 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T48 | 366-372 | Body_part | denotes | genome | http://purl.org/sig/ont/fma/fma84116 |
T49 | 446-449 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T50 | 650-656 | Body_part | denotes | genome | http://purl.org/sig/ont/fma/fma84116 |
T51 | 846-851 | Body_part | denotes | lungs | http://purl.org/sig/ont/fma/fma68877 |
T52 | 908-913 | Body_part | denotes | lipid | http://purl.org/sig/ont/fma/fma67264 |
T53 | 968-973 | Body_part | denotes | lungs | http://purl.org/sig/ont/fma/fma68877 |
T54 | 1071-1076 | Body_part | denotes | lungs | http://purl.org/sig/ont/fma/fma68877 |
T55 | 1167-1192 | Body_part | denotes | alveolar epithelial cells | http://purl.org/sig/ont/fma/fma62499 |
T56 | 1187-1192 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T57 | 1200-1204 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T58 | 1288-1292 | Body_part | denotes | gene | http://purl.org/sig/ont/fma/fma74402 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T4 | 1200-1204 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T5 | 1612-1617 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T25 | 686-690 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T26 | 1089-1098 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T27 | 1344-1359 | Disease | denotes | viral infection | http://purl.obolibrary.org/obo/MONDO_0005108 |
T28 | 1350-1359 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T29 | 1425-1430 | Disease | denotes | Ebola | http://purl.obolibrary.org/obo/MONDO_0005737 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T86 | 339-344 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T87 | 691-696 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T88 | 771-772 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T89 | 846-851 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lungs |
T90 | 968-973 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lungs |
T91 | 1071-1076 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lungs |
T92 | 1107-1108 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T93 | 1176-1204 | http://purl.obolibrary.org/obo/CL_0000082 | denotes | epithelial cells in the lung |
T94 | 1256-1257 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T95 | 1288-1292 | http://purl.obolibrary.org/obo/OGG_0000000002 | denotes | gene |
T96 | 1342-1343 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T97 | 1495-1501 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
T98 | 1513-1515 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
T99 | 1591-1592 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T100 | 1653-1654 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T24 | 29-37 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T25 | 302-318 | Chemical | denotes | oligonucleotides | http://purl.obolibrary.org/obo/CHEBI_7754 |
T26 | 606-621 | Chemical | denotes | oligonucleotide | http://purl.obolibrary.org/obo/CHEBI_7754 |
T27 | 801-817 | Chemical | denotes | oligonucleotides | http://purl.obolibrary.org/obo/CHEBI_7754 |
T28 | 908-913 | Chemical | denotes | lipid | http://purl.obolibrary.org/obo/CHEBI_18059 |
T29 | 914-927 | Chemical | denotes | nanoparticles | http://purl.obolibrary.org/obo/CHEBI_50803 |
T30 | 1644-1649 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 100-111 | http://purl.obolibrary.org/obo/GO_0009056 | denotes | degradation |
T5 | 1344-1359 | http://purl.obolibrary.org/obo/GO_0016032 | denotes | viral infection |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T59 | 0-112 | Sentence | denotes | Beyond targeting the surface proteins of 2019-nCoV, one could also target the RNA genome itself for degradation. |
T60 | 113-376 | Sentence | denotes | This RNA genome sequence of 2019-nCoV was recently published (GenBank: MN908947.3), and one strategy that could be considered then, is the use of small interfering RNA (siRNA) or antisense oligonucleotides (ASO) to combat the virus by targeting its RNA genome 23. |
T61 | 377-424 | Sentence | denotes | The challenge with this strategy is multi-fold. |
T62 | 425-493 | Sentence | denotes | First, the conserved RNA sequence domains of CoV-2019 are not known. |
T63 | 494-631 | Sentence | denotes | Identifying conserved sequences is essential in order to optimize siRNA targeting and avoid viral escape of the oligonucleotide strategy. |
T64 | 632-770 | Sentence | denotes | One could look at genome homology of 2019-nCoV to the SARS virus for comparison of conserved sequences, but this would still be guesswork. |
T65 | 771-852 | Sentence | denotes | A second challenge is how the oligonucleotides would be delivered into the lungs. |
T66 | 853-977 | Sentence | denotes | Advances have been made into delivery vehicles such as lipid nanoparticles that can mediate some delivery into the lungs 24. |
T67 | 978-1143 | Sentence | denotes | It is unknown, however, if enough siRNA’s or ASO’s would be effectively delivered within the lungs to stop the infection or make a difference in its clinical course. |
T68 | 1144-1360 | Sentence | denotes | For example, if 25% of alveolar epithelial cells in the lung had siRNA or ASO in them, that efficiency might be a great success for traditional gene therapy, but would hardly make any difference in a viral infection. |
T69 | 1361-1516 | Sentence | denotes | Such an explanation is also likely why siRNA candidates against Ebola failed in trials 25, despite significant success in preclinical animal models 26, 27. |
T70 | 1517-1681 | Sentence | denotes | Lastly, even if one assumed that siRNA was effective clinically, there is a limited ability to scale up manufacturing of siRNA drugs to a large infected population. |
T71 | 1682-1835 | Sentence | denotes | Current siRNA and ASO therapies are manufactured for rare diseases, and there are no available resources existing to manufacture the medications quickly. |